Treatment of CD79B Mutant Relapsed/Refractory Diffuse Large B-Cell Lymphoma With Bruton Tyrosine Kinase Inhibitor Zanubrutinib

Clinical trial NCT05068440 · COMPLETED

Trial details

NCT number: NCT05068440
Sponsor: BeiGene
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Relapsed Diffuse Large B-cell Lymphoma Refractory Diffuse Large B-cell Lymphoma

Start date: 2021-08-11
Primary completion: 2025-03-31
Enrollment: 65

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.